{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000512","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.174361+00:00","generated_at":"2026-06-28T09:13:07.304140+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Regen Biopharma signs non-binding LOI to acquire 95% of Canary Oncoceutics for $1M cash and stock","bullets":["Consideration: $1,000,000 cash plus common shares valued at RGBP's average share price pre-closing.","Closing contingent on raising $50,000,000 solely for Canary diagnostics and product development.","Milestone payments up to $10,000,000 per test product, including $3M upon FDA approval.","Earned royalty on net sales: 2.5% up to $250M, 4% up to $500M, 5% above $500M.","IP licensed from Cornell University enables patient-derived tumor vascular nets for drug testing."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000512","json":"https://secwatch.observer/filing/0001607062-21-000512.json","markdown":"https://secwatch.observer/filing/0001607062-21-000512.md","text":"https://secwatch.observer/filing/0001607062-21-000512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000512/0001607062-21-000512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000512/rgbp111221form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:13:07.304140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}